Greg Sullivan, MD, Chief Scientific Officer and CEO of Bridge Therapeutics, was recently interviewed by Bronwyn Mixter of Bloomberg BNA about the abuse of gabapentinoid pain drugs. Dr. Sullivan explains how buprenorphine is a safe alternative for many of the dangerous drugs that are currently prescribed for chronic pain. In the article Dr. Sullivan discusses…
News
The latest news and views from bridge therapeutics
Managed Healthcare Executive published a story in January that gave medical doctors advice on how they can better address the opioid epidemic. The publication turned to the Chief Scientific Officer of Bridge Therapeutics, Greg Sullivan M.D., and other medical experts for their feature, Eight ways doctors can address the opioid epidemic. Dr. Sullivan, told the…
A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs.
As President Trump promises to fight the opioid epidemic, here are 14 things experts want him to know Greg Sullivan, MD, Chief Scientific Officer & CEO of Bridge Therapeutics, recently spoke with Managed Healthcare Executive for a special report entitled, “Fourteen things Trump needs to know about opioids.” Managed Healthcare Executive is read by 40,000…
CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives (PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference…